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ABSTRACT
Objective: The focus of this study is to develop the formation mefenamic acid (MFA) - nicotinamide (NCT) co-crystal by using melt crystallization 
method and investigate its solubility.
Methods: Co-crystal was prepared by using melt crystallization method of MFA-NCT (1:2) at (220±3°C). The initial co-crystal formation was 
performed by powder X-ray diffraction (PXRD). The thin-layer chromatography (TLC) method was done to confirm the chemical stability of MFA and 
NCT due to synthesized process. The melt crystallization of MFA-NCT (1:2) was characterized by differential scanning calorimetry (DSC)/thermal 
gravimetric, infrared spectrophotometry, and scanning electron microscopy. The solubility of the melt crystallization of MFA-NCT (1:2) was evaluated 
by incubating the samples in water at 25°C and shaken for 24 hrs. The solubility of MFA was measured by ultraviolet-visible spectrophotometer.
Result: Characterization of a co-crystal MFA-NCT (1:2) including PXRD, Fourier transform infrared, DSC, and SEM have indicated the formation of new 
solid crystal phase that differs from MFA, NCT, and its physical mixture. The chromatogram of the TLC study exhibited two spot that corresponds to 
MFA and NCT. The solubility of the melt crystallization of MFA-NCT (1:2) was 57.97% higher than MFA solubility.
Conclusion: These results suggest that MFA-NCT co-crystal can be synthesized by using melt crystallization method without decomposition of its 
component and provides an opportunity for the development of MFA solid form.
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INTRODUCTION
Pharmaceutical co-crystals are defined as multiple component crystals 
in which at least one component is molecular and a solid at room 
temperature (the co-former) and forms a supramolecular synthon 
with a molecular or ionic active pharmaceutical ingredients (APIs) [1]. 
The new crystalline form may exhibit distinctive physicochemical 
properties and could in turn affect the dissolution, manufacturing, 
physical stability, permeability, and oral bioavailability of an API [2]. 
There are numerous co-crystals that have an improvement in their 
physiochemical properties as advantages in manufacturing such as 
carbamazepine-cinnamic acid co-crystal (dissolution properties); 
apovincamine-terephthalic acid co-crystal (stability); and paracetamol-
dipicolinic acid co-crystal (tabletability) [3-5].
Co-crystal can be defined as crystalline complexes of two or more 
neutral molecular constituents bond together in the crystal lattice 
through noncovalent interaction, primarily hydrogen bond [6]. In crystal 
engineering, crystals can be viewed as supramolecules consisting of 
superatoms bound together with intramolecular interactions instead 
of covalent bonds. Supramolecular synthons are defined as structural 
units within supermolecules which can be formed and/or assembled 
by known or conceivable synthetic operations involving intramolecular 
interaction [7]. The key in designing co-crystals is choosing a synthon, 
which is likely to form a crystallization process.
One of such potential APIs was identified to be mefenamic acid 
(MFA), an anthranilic acid and non-steroidal anti-inflammatory 
drugs with anti-inflammatory, antipyretic, and analgesic activities. 
MFA is a Biopharmaceutics Classification System class II drug with 
low solubility and high permeability [8]. MFA has the chemical name 
2-((2,3-dimethylphenyl)amino)benzoic acid with molecular weight 
241.28 g/mol. MFA has 2 hydrogen donor and 3 hydrogen bond acceptor 
based as computed properties [9]. Structure of MFA is shown in Fig. 1. 
In the term co-crystal design, this property is useful to construct the 
hydrogen bond with co-former as the heterosynthon supramolecular 
interaction.
Chemically, MFA has a carboxylic acid functional group and amine 
functional group. In the supramolecular architecture of co-crystal 
design, MFA may exhibit a carboxylic acid-amide heterosynthon or 
carboxylic acid dimer homosynthon. In the Cambridge Structural 
Database, a carboxylic acid-amide is more favorable than carboxylic 
acid dimer homosynthon [10,11]. Nicotinamide (NCT) is one of the 
well-known co-crystal formers with carboxylic acid. The amide synthon 
in the chemical structure of NCT is a functional group that is responsible 
for co-crystallization forming of APIs such as carbamazepine, 
indomethacin, and artesunate [12-14]. The chemical structure of NCT 
is shown in Fig. 1.
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Fig. 1: The chemical structure of mefenamic acid and 
nicotinamide
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There were several co-formers that have been used to form 
supramolecular heterosython with MFA, such as NCT, isonicotinamide, 
nicotinic acid, urea, oxalic acid, 4-aminobenzoic acid, 2-aminobenzoic 
acid, pyridoxine, isonicotinic acid hydrazide, 4,4’-bipyridyl, 
2,2’-bipyridyl, and 2-aminopyride [15]. The successful MFA co-crystal 
formation was performed by 4,4’-bipyridyl by solvent evaporation 
method and NCT by neat grinding method [16]. In the pharmaceutical 
solid form development, NCT is more suitable to be used as co-former 
than 4,4’-bipyridyl. Li et al. showed the neurotoxicity of 4,4’-bipyridyl 
compound [17]. To the best of our knowledge, only one reference 
involving the successful co-crystal of MFA with NCT has been reported 
until now, which is obtained by neat grinding method. The co-
crystal of MFA-NCT by neat grinding method could only be prepared 
as polycrystalline powders, and the structure of its co-crystal was 
determined from powder diffraction data.
Therefore, the studies of MFAc-crystal with various co-formers 
especially NCT are still challenged to be explored. Although the MFA-
NCT co-crystal have been reported before by neat grinding, but there 
were several limitations of neat grinding as co-crystal synthesis 
method. The disadvantages were that grinding methods often need 
special equipment to keep the grinding frequency, and the resulting 
product often contains amorphous impurities [18]. On the other hand, 
as reported by Ulrich [19], the melt crystallization method has a positive 
aspect in high selectivity to obtain the more pure product. In this 
study, we reported the melt crystallization method as the alternative 
method in MFA-NCT co-crystal synthesis and also its solubility study. 
Physicochemical characterization was performed by powder X-ray 
diffraction (PXRD), Fourier transform infrared spectroscopy (FTIR), 
thermal analysis differential scanning calorimetry/thermal gravimetric 
analysis (DSC/TGA), and scanning electron microscope (SEM) 
observation. The chemical stability of starting component was also 
investigated by thin-layer chromatography (TLC) analysis to ensure 
that both MFA and NCT did not possess chemical decomposition during 
the heating process. The solubility was done by incubating the samples 
in water for 24 hrs. These co-crystals are expected to be more soluble in 
water than parent acids, due to the possibility of complex formation in 
solution and the higher solubility of NCT.
MATERIALS AND METHODS
Materials
MFA (2-((2,3-dimethylphenyl)amino) benzoic acid) (99.0% Pyridam), 




Physical mixtures were obtained by gentle mixing of MFA and NCT in a 
1:2 molar ratio in a glass mortar with a glass pestle for 1 minute.
Melt crystallization
The physical mixtures (2 g) of MFA and NCT (1:2 molar ratio) 
were heated in a porcelain dish on a paraffin oil bath maintained 
at 200°C. Molten mass was incubated in a vessel containing 25 ml 
water at 90°C using water bath. The obtained product was dried 
at room temperature overnight and further to be analyzed for its 
characterization.
Characterization of co-crystals
The pure drug, co-former, and the product obtained from melt 
crystallization were subjected to PXRD, TLC, FTIR, DSC/TGA, and SEM 
analyzed.
PXRD
The PXRD analysis was performed in Philips PW 1710 BASED and 
illuminated with Cu-Kα radiation (λ=1.5418) at a tube voltage of 40 kV 
and a tube current of 35 mA. The samples were analyzed over a 2θ 
range of 5-45° with increase of 0.019° at a rate of 7/minutes.
TLC analysis
TLC analysis of melt crystallization of MFA-NCT (1:2) was done for 
the identification of the parent compound decomposition as the result 
of melt crystallization process. The chloroform: Methanol (9:1) was 
designated as solvent system and the silica gel GF 254 nm as stationary 
phase. The spot detection was recorded under ultraviolet (UV) 254 nm.
FTIR spectroscopy
The spectra of drug, co-former, physical mixtures, and the melt 
crystallization product were recorded in Infrared Spectrophotometer 
(Jasco-4200 type A) and KBr beam splitter. Potassium bromide pellet 
method was employed, and background spectrum was collected. The 
range was set from 450 to 4000 cm−1 with a 4 cm−1 resolution.
DSC
Thermal analysis of drug, co-former, physical mixtures and the melt 
crystallization product were recorded on a DSC (Linseis sta pt 1600 and 
Q-20 Thermal Analysis). Thermograph was recorded under a constant 
nitrogen gas flow of 50 mL/minutes. The DSC apparatus was calibrated 
with regard to temperature and enthalpy using indium as a standard. 
The heating was set to 10 K/minutes in a range from 30 to 250°C.
SEM
The surface and shape characteristic of pure MFA, NCT, and melt 
crystallization of MFA-NCT (1:2) were studied by SEM (JEOL JSM 6510). 
Powder samples were mounted onto aluminum stub using double-
sided adhesive tape and sputter coated with a thin layer of gold at 5.6 
Torr vacuum before examination. The samples were scanned by an 
electron beam of acceleration potential of 10 kV.
Solubility study
An excess amount of MFA, physical mixture of MFA-NCT (1:2), and 
melt crystallization of MFA-NCT (1:2) were suspended in 10 ml of 
distilled water in capped glass vials, and the slurries were agitated in 
an orbital shaker (150 rpm/minutes) at room temperature for 24 hrs. 
After 24 hrs, the suspension was filtered through a paper filter, and 
the amount of drug solubilized was analyzed spectrophotometrically 
(UV-1800, Shimadzu, Japan) at 330 nm. The solubility experiments 
were conducted in triplicate.
RESULT
PXRD analysis
The result of PXRD analysis of MFA, NCT, its physical mixture, and melt 
crystallization product is shown in Fig. 2. The diffractogram of MFA 
showed characteristic peak at 2θ value of 6.4°; 21.35°; and 26.21°, 
and NCT exhibited diffractogram peak 2θ at 14.7°; 22.1°; 23.3°; 25.7°; 
and 27.2°. The physical mixture showed diffractogram combination of 
both starting components. The diffractogram of melt crystallization of 
Fig. 2: The X-ray powder diffraction patterns of mefenamic acid 
(MFA) form I (a), nicotinamide (NCT) (b), physical mixture of 
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MFA-NCT showed new peaks at 2θ value of 7.2°; 9.3°; 12.1°; and 15.4° 
(Fig. 2).
TLC analysis
The result of TLC analysis of the melt crystallization of MFA-NCT (1:2) 
exhibited two spot that corresponds to the spots of MFA and NCT 
pure compound (Fig. 3). The MFA eluated in Rf: 0.85, whether NCT at 
Rf: 0.68. Except the two spots above, there was not observed another 
spot of melt crystallization of MFA-NCT product.
FTIR spectroscopy analysis
The FTIR spectrum of MFA showed characteristic peak with high 
intensity at 1650 cm−1, presenting C=O functional group (Fig. 4), 
3305 cm−1 as vibration of N-H functional group and carboxylic acid at 
1253 cm−1. The NCT spectrum exhibited the N-H stretching at 3370 cm−1 
and 3162 cm−1 and C=O functional group at 1681 cm−1. The spectrum 
of physical mixture showed characteristic peaks of MFA and NCT. The 
melt crystallization of MFA-NCT (1:2) exhibited spectrum at 1654 cm−1, 
1249 cm−1, 3166 cm−1, 3363 cm−1, and two new bands at 2360 cm−1 and 
1932 cm−1. In the fingerprint region (1500-500 cm−1), the result was 
presented the same spectrum pattern.
Thermal analysis
The thermal behavior of each sample (MFA, NCT, its physical mixture, 
and melt crystallization) was recorded by DSC-TGA. The MFA showed 
two endothermic peaks at 168.9°C and 230.1°C as MFA form I. NCT only 
showed an endothermic peak at 129.9°C as melting point. The physical 
mixture of MFA-NCT (1:2) showed an endothermic peak at 122.1°C. 
The DSC parameters of MFA, NCT, its physical mixture, and the melt 
crystallization of MFA-NCT (1:2) are presented in Fig. 5 and Table 1.
SEM
SEM analysis was performed for the pure MFA, co-former NCT, and the 
melt crystallization of MFA-NCT (1:2). The pure MFA exhibited cube 
shape with rough surface; the co-former NCT showed cube shape with 
long size and smooth surface. The melt crystallization of MFA-NCT (1:2) 
presented a cube shape with smooth surface and showed reducing of 
particle size (Fig. 6).
Solubility study
The solubility test was done with the standard pure MFA, the physical 
mixture of MFA-NCT (1:2), and the melt crystallization of MFA-NCT 
(1:2) by dissolving the samples in the distilled water equipped with 
an orbital shaker at room temperature and was done in triplicate. 
The results from the solubility test were then measured with a 
spectrophotometer UV-visible absorbance maximum of 332 nm. The 
results are shown in Table 2.
DISCUSSION
The new crystalline phase of interaction experiment between 
two components can be identified by PXRD method. If the new 
crystalline phases are formed from the interaction between the two 
components [20], it will show clearly from X-ray diffractogram. The 
different diffractogram pattern showed differences in the character of 
the crystal lattice. By comparing the diffractogram pattern of its starting 
components, its physical mixture, and the product of co-crystallization 
experiment, the new solid phase formation can be adjusted [21,22]. 
Fig. 3: Thin-layer chromatography profile of mefenamic acid 
(MFA), nicotinamide (NCT), physical mixture of MFA-NCT (1:2), 
and the melt crystallization of MFA-NCT (1:2)
Fig. 5: The differential scanning calorimetry profiles of 
mefenamic acid (MFA) form I, nicotinamide (NCT) and the melt 
crystallization of MFA-NCT (1:2) (a) and thermal gravimetric 
analysis result of the melt crystallization of MFA-NCT (1:2) (b)
ba
Fig. 6: The scanning electron microscope of mefenamic acid 




Fig. 4: The Fourier transform infrared pattern of nicotinamide 
(NCT) (a), mefenamic acid (MFA) form I (b), physical mixture 
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This result was relevant to MFA-NCT co-crystal diffractogram reported 
by Fabian et al., 2011, that have been synthesized by the neat grinding 
method. Based on PXRD analysis, the melt crystallization of MFA-NCT 
(1:2) exhibited a co-crystal formation.
Furthermore, the co-crystal formation of melt crystallization of MFA-
NCT (1:2) confirmed by several analytical methods such as FTIR 
spectrophotometry, thermal analysis (DSC-TGA), SEM, and also the 
TLC method for the possibilities of chemical decomposition of starting 
component as heating process consequences.
In the pharmaceutical co-crystal term, the interaction between API and 
co-former was only exhibiting the hydrogen bond or noncovalent bond 
that can be separated as a parent compound during the dissolution 
process [23]. The new compound forming was not being expected 
in co-crystallization process. In some case, the melt crystallization 
method triggered the chemical decomposition and resulted in the 
new compound that differs with parent compound. Nugrahani et al. 
reported the chemical decomposition of MFA with oxalic acid during 
the melting process [24].
As shown in Fig. 3, the TLC analysis of the melt crystallization product 
resulted two spot that corresponds to MFA and NCT. This result was 
indicated that MFA and NCT did not possess chemical decomposition 
or other chemical reaction during heating process. This finding was 
also supported by FTIR spectrum of the melt crystallization product 
as shown in the fingerprint region. The importance of the fingerprint 
region is that each different compound produces a different pattern 
of troughs in this part of the spectrum [25]. As mentioned in the 
FTIR result, in the fingerprint region, all samples presented the same 
spectrum pattern.
Despite that, the FTIR analysis was also used as co-crystal analytical 
method for co-crystal formation due to the formation of the hydrogen 
bond between API and co-former. The hydrogen bond of API and co-
former is identified as the result of synthon-synthon interaction. The 
possibilities of the hydrogen bond formation in the melt crystallization 
of MFA-NCT (1:2) can be identified by FTIR and compared to the 
starting components and their physical mixture.
In the melt crystallization of MFA-NCT (1:2), there were occurred 
three major wavenumber shifting of FTIR spectrum. First, the ν(C=O) 
stretching band of MFA (1650 cm−1) and NCT (1681 cm−1) were fused 
and appeared in the co-crystal spectrum at 1654 cm−1. The fused and 
shifting of C=O was due to the possibilities of hydrogen bond formation 
between the C=O of MFA and the NH2 of NCT. Second, there was shifting 
from N-H vibration of NCT to lower frequency from 3370 cm−1 to 
3363 cm−1 and from 3162 cm−1 to 3166 cm−1. And the third, there was 
also the new band spectrum at 2360 cm−1 and 1932 cm−2. The new 
band spectrum was also reported by Neurohr et al in the formation 
of naproxen-nicotinamide co-corystal. The new band spectrums were 
appeared in 2525 cm-1 and 1982 cm-1 and adjusted as O-Hcarboxylic acid 
Naromatic hydrogen bond [26]. According to this report, the present 
new band in melt crystallization of MFA-NCT (1:2) was also predicted 
as hydrogen bond formation of O-Hcarboxylic acid of MFA and Naromatic of NCT. 
Based on FTIR analysis, there was predicted the co-crystal formation of 
MFA and NCT as indicated by hydrogen bond occurrences.
Moreover, the thermal behavior of each sample was identified by 
thermogram analysis. The different melting transition from individual 
components suggests the formation of co-crystal [27]. As shown in 
Fig. 5, the new endothermic peak of melt crystallization of MFA-NCT 
(1:2) was presented at 125.9°C, lower than melting point of each 
component and higher than its physical mixture. Although the thermal 
pattern was similar to its physical mixture (mp: 122.1°C), the energy 
used was quite different as shown in Table 1 and Fig. 5a and b. The 
average endothermic energy of melt crystallization of MFA-NCT was 
shown to be higher than its physical mixture. The higher endothermic 
energy indicated that the melt crystallization product was more 
crystalline than its physical mixture. The thermogravimetric analysis 
showed that the melt crystallization of MFA-NCT (1:2) was stable up 
to 200°C before it was decomposed (Fig. 5b). A single endothermic 
transition of the melt crystallization of MFA: NCT (1:2) demonstrated 
that the new solid phase has been formed as co-crystal form, stable 
below its melting points and also the absence of unbound or absorbed 
solvent and water [28]. The presence of absorbed solvent and water 
in the co-crystal can influence the stability of co-crystal during 
manufacturing process or storage. In the other words, this co-crystal 
was very potentially to be developed in a solid dosage form.
As the prosperity of co-crystal formation, we evaluated the solubility 
of MFA-NCT co-crystal in distilled water. The solubility study was also 
done in pure MFA and its physical mixture. The solubility of the melt 
crystallization of MFA-NCT (1:2) was differed significantly to pure 
MFA and its physical mixture. The solubility of melt crystallization 
of MFA-NCT (1:2) was 57.97% higher than pure MFA. The solubility 
of pure MFA was lower than the melt crystallization of MFA-NCT 
(1:2) suggested because of the formation of hydrogen bond between 
MFA and NCT that increased the solubility of MFA. From the SEM 
analysis (Fig. 6), there was observed the smaller particle size of melt 
crystallization of MFA-NCT (1:2). Reducing of particle size was also 
contributing to the higher solubility of the melt crystallization of MFA-
NCT (1:2). The other factor that influences the solubility of APIs was 
a decrease in energy of crystal lattice by co-crystal formation such 
as in paclixacel-naringenin and simvastatin-tartaric acid co-crystal 
formation [29,30].
Based on the result and discussion mentioned above, the co-crystal of 
MFA-NCT has been successfully synthesized by melt crystallization. 
The future development is exploring the physicochemical changes that 
influence in MFA manufacturing such as dissolution rate and also its 
stability. This finding is very useful in the development of MFA solid 
dosage form that has better physicochemical properties.
Table 2: The solubility of pure MFA, physical mixture of 
MFA-NCT (1:2), and the melt crystallization of MFA-NCT (1:2) in 
distilled water
Samples Concentration (µg/mL)
1 2 3 Mean±SD
Pure MFA 6.65 6.83 6.35 6.62±0.23
Physical mixture of 
MFA-NCT (1:2)
7.35 7.18 7.52 7.35±0.17
The melt crystallization of 
MFA-NCT (1:2)
10.69 10.06 10.58 10.45±0.34
SD: Standard deviation, DSC: Differential scanning calorimetry, 
NCT: Nicotinamide, MFA: Mefenamic acid, The data shown as mean±SD, n=3
Table 1: The DSC parameters of MFA, NCT, its physical mixture, and the melt crystallization of MFA-NCT (1:2)
Samples Endothermic (°C) Enthalpy (J/g) Endothermic (°C) Enthalpy (J/g)
Mefenamic acid 168.9 −7.74 230.1 −337.66
Nicotinamide 129.6 −221.71 254 −57.79
Physical mixture 122.1 −54.41 - -
Melt crystallization 125.9 −82.43 269.6 −122.32
DSC: Differential scanning calorimetry, NCT: Nicotinamide, MFA: Mefenamic acid
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CONCLUSION
This study first reports that the co-crystal of MFA-NCT (1:2) has 
been synthesized successfully by using melt crystallization method. 
The solubility evaluation of MFA-NCT co-crystal (1:2) had increased 
significantly compared to MFA and its physical mixture. The 
confirmations against co-crystal MFA-NCT (1:2) had indicated the 
formation of new solid crystalline phases that differ from MFA and its 
physical mixture.
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